Abrdn Life Sciences Investors Form 4 insider transactions

Saba Capital Management, a significant shareholder in abrdn Life Sciences Investors, has sold 11,674 shares of common stock at a price of $14.12 per share.

Bill Maher, a director of abrdn Life Sciences Investors, recently acquired 650 shares of common stock through an indirect purchase by spouse.

Director Rose DiMartino purchased 1,000 shares of abrdn Life Sciences Investors (HQL) at $15.53 per share on July 16, 2024.

Saba Capital Management, L.P. reports an increase in its holdings of abrdn Life Sciences Investors (HQL) common stock.

Saba Capital Management, L.P. reports purchasing 13,812 shares of abrdn Life Sciences Investors (HQL) at $14.08 per share, increasing their holdings.

Saba Capital Management, L.P. reports increased beneficial ownership of abrdn Life Sciences Investors (HQL) common stock through recent purchases.

Saba Capital Management, L.P. reports purchasing additional shares of abrdn Life Sciences Investors, increasing its beneficial ownership.

Saba Capital Management, L.P. reports increased ownership in abrdn Life Sciences Investors (HQL) through recent stock purchases.

Saba Capital Management, L.P. reports increased ownership in abrdn Life Sciences Investors (HQL) through recent stock purchases.

Saba Capital Management, L.P. reports purchasing additional shares of abrdn Life Sciences Investors, increasing its beneficial ownership.

Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors (HQL), has increased its holdings through a series of open market purchases.

Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors (HQL), acquired 1,303 shares of common stock at $13.50 per share on May 23, 2024, increasing their indirect holdings to 3,251,883 shares.

Saba Capital Management, L.P. reports purchasing 34,755 shares of abrdn Life Sciences Investors (HQL) at $14.19 per share, increasing their holdings to 3,250,580 shares.

Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), acquired 57,862 shares of common stock at $13.86 per share on May 10, 2024, increasing its total holdings.

Saba Capital Management, L.P. reports increased ownership in abrdn Life Sciences Investors (HQL) through recent stock purchases.

Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), has increased its holdings through recent stock purchases.

Saba Capital Management, L.P. reports increased beneficial ownership of abrdn Life Sciences Investors (HQL) common stock through recent purchases.

Saba Capital Management, along with Boaz Weinstein, reports an acquisition of additional shares in abrdn Life Sciences Investors (HQL), increasing their beneficial ownership.

Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors, purchased 120,304 shares of common stock at $13 per share on April 26, 2024, increasing its indirect holdings to 3,025,602 shares.

Saba Capital Management, L.P. reports increased ownership in abrdn Life Sciences Investors (HQL) through recent common stock purchases.

Saba Capital Management, along with Boaz Weinstein, reports increased beneficial ownership in abrdn Life Sciences Investors (HQL) through recent common stock purchases.

Saba Capital Management, L.P. reports increased beneficial ownership of abrdn Life Sciences Investors (HQL) common stock through open market purchases.

Kathleen Goetz, a director of abrdn Life Sciences Investors, purchased 400 shares of common stock at a price of $13.3183 per share on April 9, 2024.